

L.A. GARBUTT<sup>1</sup>, A.J. DENISUIK<sup>2</sup>, H.J. ADAM<sup>2,3</sup>, M. BAXTER<sup>2</sup>, P.R.S. LAGACÉ-WIENS<sup>2,3</sup>, J.A. KARLOWSKY<sup>2,3</sup>, D.J. HOBAN<sup>2,3</sup>, G.G. ZHANEL<sup>2</sup>, and the CANADIAN ANTIMICROBIAL RESISTANCE ALLIANCE (CARA)<sup>1</sup>Department of Internal Medicine, <sup>2</sup>Department of Medical Microbiology, University of Manitoba, <sup>3</sup>Diagnostic Services Manitoba, Winnipeg, MB, Canada

## UPDATED ABSTRACT

**Objective:** The purpose of this study was to assess the antimicrobial susceptibility patterns of bacterial pathogens isolated from Canadian ICUs from 2007 to 2014.

**Methods:** From 2007 to 2014 inclusive, tertiary care centres from across Canada submitted 36,607 bacterial isolates as part of the Canadian ward surveillance study (CANWARD). Of these, 6,978 (19.1%) were from patients on ICUs. Bacterial isolates were collected from blood, urine, wound, and respiratory specimens. Susceptibility testing was carried out using Clinical and Laboratory Standards Institute (CLSI) guidelines. Minimum inhibitory concentration interpretive criteria were defined by CLSI breakpoints.

**Results:** Of the 6,978 bacterial pathogens collected in this study, 57.1%, 37.1%, 3.2%, and 2.6% of isolates were from respiratory, blood, wound, and urine specimens, respectively. The top five organisms isolated from Canadian ICUs were: *Staphylococcus aureus* (21.0%), *Pseudomonas aeruginosa* (10.4%), *E. coli* (10.3%), *Streptococcus pneumoniae* (6.8%), and *Klebsiella pneumoniae* (6.3%). Susceptibility rates (SR) for MRSA were: 100% vancomycin (VAN), 100% televancin, 100% linezolid (LZD), 99.7% daptomycin (DAP), 99.7% tigecycline (TGC), and 49.5% clindamycin (CLD), respectively. SR for *E. coli* and *K. pneumoniae* were: 99.9% meropenem (MER), 98.8% ertapenem (ERT), 97.3% TGC, 94.8% piperacillin-tazobactam (PTZ), 91.2% gentamicin (GEN), 89.3% ceftriaxone, and 81.0% ciprofloxacin (CIP), respectively. SR for *P. aeruginosa* were: 95.4% amikacin, 94.4% colistin, 81.9% GEN, 76.9% ceftazidime, 75.9% PTZ, 74.9% CIP, and 74.1% MER, respectively. SR for *S. pneumoniae* were: 99.6% levofloxacin, 94.2% CLD, 87.4% doxycycline, 85.9% TMP-SMX, 83.3% penicillin, and 83.2% clarithromycin. Among the 1,453 *S. aureus* collected, 21.7% were MRSA, while 9.2% of 716 *E. coli* produced an ESBL, with the rate of ESBL-producing *E. coli* increasing from 2.5% in 2007 to 19.1% in 2014 ( $P < 0.001$ ).

**Conclusions:** MER, ERT, TGC, and PTZ were the most active agents against Gram-negative bacilli (susceptibility >94.8%). Against MRSA, SR of >99% were observed for VAN, LZD, TGC, and DAP. The proportion of ESBL-producing *E. coli* has increased significantly in Canadian ICUs since 2007.

## BACKGROUND

Subsequent to antimicrobial resistance data published from the Canadian National Intensive Care Unit (CAN-ICU) study (2005-2006) on 4,180 bacterial isolates from ICU patients [1], there has been a paucity of national surveillance data concerning antimicrobial susceptibility rates in Canadian ICUs. Antibiotic utilization and over-utilization both in hospitals and the community is a strong impetus for antibiotic-resistant pathogens such as MRSA, extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* and *Klebsiella species*, carbapenem-resistant *Enterobacteriaceae*, and multidrug-resistant *Pseudomonas aeruginosa* [1,2]. It is estimated that 30-50% of antibiotic use in hospitals is unjustified [3]. Each year in the United States, more than 2 million people become infected with bacteria that are resistant to antibiotics and at least 23,000 people die each year as a direct result of resistant infections [4]. Infections caused by antibiotic-resistant organisms are associated with longer hospital stays, costly or prolonged treatments, and increased morbidity and mortality when compared to antibiotic-susceptible infections [5]. The ICU utilizes the most antibiotics and has the highest resistance rates. It is estimated that 70% of ICU patients are on antibiotics at any one time [6]. While available evidence suggests that antimicrobial stewardship interventions are effective in ICUs, stewardship is encumbered by the inherent severity of illness in ICU patients [7].

## REFERENCES

[1] Zhanel G, DeCorby M, Laing N et al. Antimicrob Agents and Chemother. 2008. 52:1430-1437. [2] Zhanel G, Adam H, Baxter M et al. J Antimicrob Chemother. 2013. 68(Suppl1):i7-122. [3] Hecker M, Aron D, Patel N et al. Arch Intern Med. 2003. 163:972-8. [4] Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. U.S. Department of Health and Human Services. [5] Dellit T, Owens R, McGowan J et al. Clin Infect Dis. 2007. 44:159-77. [6] Vincent J, Marshall J et al. JAMA. 2009. 302:2323-9. [7] Kaki R, Ellingsen M, Walker S et al. J Antimicrob Chemother. 2011. 66:1223-1230.

## MATERIALS &amp; METHODS

**Bacterial Isolates:** A total of 36,607 bacterial isolates (isolated from blood, urine, wound, and respiratory specimens) were submitted by tertiary-care medical centres from January 2007 to December 2014, inclusive, as part of the ongoing CANWARD national surveillance study [2]. Of these, 6,978 (19.1%) were from patients admitted to an intensive care unit. The medical centres were asked to submit clinical isolates (consecutive, one per patient, per infection site) that were "clinically significant" (ie. from patients with a presumed infectious disease). Surveillance swabs, ear, eye, nose, and throat swabs were not included. Anaerobic organisms were not included. Isolates were shipped on Amies semi-solid transport media to the Health Sciences Centre laboratory in Winnipeg, MB, Canada. Isolates were subcultured onto appropriate media and stocked in skim milk at -80° C until minimum inhibitory concentration (MIC) testing was carried out.

**Antimicrobial Susceptibility Testing:** Following 2 subcultures from frozen stock, *in vitro* antimicrobial susceptibility testing was performed using the broth microdilution method in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines (CLSI M07-A9). Minimum inhibitory concentration interpretive standards were defined by CLSI M100-S24 breakpoints. US Food and drug administration (FDA) breakpoints were used for colistin (S:  $\leq 2$ , R:  $\geq 4$   $\mu\text{g/ml}$ ). Antimicrobial agents were obtained as laboratory grade powders from their respective manufacturers. Stock solutions were prepared and dilutions made as described by CLSI. The MICs were determined using 96-well custom designed microtitre plates. These plates contained doubling antimicrobial dilutions in 100  $\mu\text{l}$ /well of cation adjusted Mueller-Hinton broth and inoculated to achieve a final concentration of approximately  $5 \times 10^5$  CFU/ml. Microtitre panels were then incubated in ambient air at 35°C ( $\pm 2^\circ\text{C}$ ) for 24 hours prior to reading. Colony counts were performed periodically to confirm inocula. Quality control was performed using ATCC organisms including:

*S. aureus* 29213, *E. faecalis* 29212, *E. coli* 25922, and *P. aeruginosa* 27853.

**Statistical Analysis:** Statistical significance was calculated by the chi-squared test or the Fisher exact test using the SPSS statistics (Version 20) program (IBM Corporation).

## CONCLUSIONS

1. The most commonly isolated pathogens in Canadian ICUs were: *S. aureus*, *P. aeruginosa*, *E. coli*, *S. pneumoniae*, and *K. pneumoniae*.

- ICU patients in this study were most commonly males ages 18-64 with respiratory tract infections.

2. Meropenem and piperacillin-tazobactam showed the greatest activity against Gram-negative bacilli in this study (susceptibility >94.6%). Against *P. aeruginosa*, susceptibility rates were greatest for amikacin (95.4%), colistin (94.5%), and gentamicin (81.9%)

3. Vancomycin, linezolid, tigecycline, and daptomycin demonstrated >99% susceptibility against MRSA isolates tested.

4. The prevalence of relevant antimicrobial-resistant organisms in Canadian ICUs was as follows:

- MRSA reached peak incidence in 2008 (32.4%), however, from 2009 to 2014 MRSA rates declined and remained fairly constant between 17% and 20.4%.
- Carbapenem-resistant *Enterobacteriaceae* are yet to emerge as a significant threat in Canadian ICUs.
- While rates were somewhat variable, ESBL-producing *E. coli* now represent a significant proportion (2014: 18.6%) of *E. coli* isolated from the ICU.

## ACKNOWLEDGMENTS

The authors would like to thank the participating centers, investigators, and laboratory site staff. The CANWARD study is supported in part by Abbott Laboratories, Astellas Pharma Canada, AstraZeneca, Cubist Pharmaceuticals, Merck Canada Inc., Optimer Pharmaceuticals, Pfizer, Sunovion Pharmaceuticals, The Medicines Company, Theravance, Triton Pharma, and Trius Therapeutics.

## RESULTS

Table 1. Antimicrobial susceptibility testing of Gram-negative and Gram-positive pathogens isolated from Canadian ICUs.

Gram-negative pathogens								Gram-positive pathogens															
Organism (n)	%S	%I	%R	MIC ( $\mu\text{g/ml}$ )				Organism (n)	%S	%I	%R	MIC ( $\mu\text{g/ml}$ )				Organism (n)	%S	%I	%R	MIC ( $\mu\text{g/ml}$ )			
Antimicrobial				MIC <sub>50</sub>	MIC <sub>90</sub>	Min	Max	Antimicrobial				MIC <sub>50</sub>	MIC <sub>90</sub>	Min	Max	Antimicrobial				MIC <sub>50</sub>	MIC <sub>90</sub>	Min	Max
<b>P. aeruginosa (724)</b>								<b>E. coli (718)</b>								<b>K. pneumoniae (439)</b>							
Amikacin	95.4	1.9	2.6	4	16	$\leq 2$	>64	Amikacin	99.0	1.0		$\leq 2$	4	$\leq 2$	32	Amikacin	99.8		0.2	$\leq 2$	$\leq 2$	$\leq 2$	>64
AMC				>32	>32	0.5	>32	AMC	77.4	13.0	9.6	8	16	0.5	>32	AMC	92.3	4.2	3.5	2	8	0.5	>32
Cefazolin				>128	>128	$\leq 0.5$	>128	Cefazolin	60.1	12.5	27.4	2	>128	$\leq 0.5$	>128	Cefazolin	79.7	6.4	13.9	2	16	$\leq 0.5$	>128
Cefoxitin				>32	>32	4	>32	Cefoxitin	87.2	5.5	7.3	4	16	$\leq 0.06$	>32	Cefoxitin	89.1	4.0	6.9	4	16	0.5	>32
Ceftazidime	77.0	6.6	16.4	4	32	$\leq 0.5$	>32	Ceftazidime	87.7	1.8	10.5	$\leq 0.5$	16	$\leq 0.5$	>32	Ceftazidime	94.7	0.6	4.7	$\leq 0.5$	1	$\leq 0.5$	>32
Ceftriaxone				32	>64	$\leq 1$	>64	Ceftriaxone	86.2	0.6	13.2	$\leq 1$	16	$\leq 1$	>64	Ceftriaxone	94.3		5.7	$\leq 1$	$\leq 1$	$\leq 1$	>64
Ciprofloxacin	74.7	8.3	17.0	0.25	8	$\leq 0.06$	>16	Ciprofloxacin	72.7	0.4	26.8	$\leq 0.06$	>16	$\leq 0.06$	>16	Ciprofloxacin	94.3	1.8	3.9	$\leq 0.06$	0.5	$\leq 0.06$	>16
Colistin	94.5		5.5	1	2	$\leq 0.06$	>16	Colistin	98.9		1.1	0.25	0.5	$\leq 0.06$	>16	Colistin	97.5		2.5	0.5	1	$\leq 0.06$	>16
Ertapenem				16	>32	0.12	>32	Ertapenem	98.6	0.6	0.8	$\leq 0.06$	0.06	$\leq 0.06$	>32	Ertapenem	99.3	0.7		$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	1
Gentamicin	81.9	7.5	10.6	2	16	$\leq 0.5$	>32	Gentamicin	87.8	0.7	11.5	$\leq 0.5$	32	$\leq 0.5$	>32	Gentamicin	96.8		3.2	$\leq 0.5$	$\leq 0.5$	$\leq 0.5$	>32
Meropenem	74.0	8.3	17.7	1	16	$\leq 0.12$	>32	Meropenem	99.9		0.1	$\leq 0.12$	$\leq 0.12$	$\leq 0.12$	32	Meropenem	100.0			$\leq 0.12$	$\leq 0.12$	$\leq 0.12$	0.25
Moxifloxacin				2	>16	$\leq 0.06$	>16	Moxifloxacin				$\leq 0.06$	>16	$\leq 0.06$	>16	Moxifloxacin				0.12	1	$\leq 0.06$	16
TZP	76.0	14.4	9.7	8	64	$\leq 1$	512	TZP	94.6	1.7	3.8	2	8	$\leq 1$	>512	TZP	95.2	2.1	2.7	2	8	$\leq 1$	>512
Tigecycline				16	>16	0.25	>16	Tigecycline	100.0			0.25	1	0.12	2	Tigecycline	92.9	5.5	1.6	1	2	0.25	8
SXT				8	>8	$\leq 0.12$	>8	SXT	71.4		28.6	$\leq 0.12$	>8	$\leq 0.12$	>8	SXT	93.6		6.4	$\leq 0.12$	1	$\leq 0.12$	>8
<b>MSSA (1149)</b>								<b>MRSA (317)</b>								<b>S. pneumoniae (474)</b>							
Cefazolin				$\leq 0.5$	1	$\leq 0.5$	8	Cefazolin				128	>128	1	>128	AMC	97.3	2.0	0.7	$\leq 0.06$	0.25	$\leq 0.06$	8
Ciprofloxacin	89.7	2.3	8.0	0.5	2	$\leq 0.06$	>16	Ciprofloxacin	15.8	0.3	83.9	>16	>16	0.25	>16	Ceftriaxone	99.3	0.4	0.2	$\leq 0.12$	0.12	$\leq 0.12$	>16
Clarithromycin	77.8	0.5	21.6	0.25	>16	$\leq 0.25$	>16	Clarithromycin	16.1	0.3	83.5	>16	>16	$\leq 0.25$	>16	Cefuroxime	91.5	3.1	5.4	$\leq 0.25$	0.5	$\leq 0.25$	>16
Clindamycin	94.6		5.4	$\leq 0.25$	$\leq 0.25$	$\leq 0.25$	>8	Clindamycin	49.4		50.6	>8	>8	$\leq 0.25$	>8	Clarithromycin	83.2	3.8	13.0	$\leq 0.03$	2	$\leq 0.03$	>32
Daptomycin	100.0			0.25	$\leq 0.25$	$\leq 0.06$	1	Daptomycin	99.7		0.3	0.25	0.5	0.06	2	Clindamycin	94.2	0.2	5.6	$\leq 0.12$	$\leq 0.12$	$\leq 0.12$	>8
Gentamicin	99.0	0.2	0.9	$\leq 0.5$	$\leq 0.5$	$\leq 0.5$	>32	Gentamicin	86.4		13.6	$\leq 0.5$	>32	$\leq 0.5$	>32	Doxycycline	87.5	1.3	11.2	$\leq 0.25$	1	$\leq 0.25$	>16
Linezolid	99.9		0.1	2	2	$\leq 0.12$	8	Linezolid	100.0			2	2	$\leq 0.12$	4	Levofloxacin	99.6	0.2	0.2	1	1	$\leq 0.06$	8
Moxifloxacin	93.0	0.3	6.8	$\leq 0.06$	0.12	$\leq 0.06$	>16	Moxifloxacin	16.4	3.2	80.4	8	>16	$\leq 0.06$	>16	Linezolid	100.0			1	1	$\leq 0.12$	2
Tigecycline	99.9		0.1	0.12	0.25	$\leq 0.03$	1	Tigecycline	99.7		0.3	0.25	0.5	0.12	1	Moxifloxacin	99.6	0.4		0.12	0.25	$\leq 0.06$	2
SXT	99.7		0.3	$\leq 0.12$	$\leq 0.12$	$\leq 0.12$	>8	SXT	88.3		11.7	$\leq 0.12$	8	$\leq 0.12$	>8	Penicillin	83.3	11.4	5.3	$\leq 0.03$	0.5	$\leq 0.03$	4
Vancomycin	100.0			1	1	$\leq 0.25$	2	Vancomycin	100.0			1	1	$\leq 0.25$	2	Vancomycin	85.9	4.9	9.2	$\leq 0.12$	2	$\leq 0.12$	>8

MSSA: methicillin-susceptible *S. aureus*, MRSA: methicillin-resistant *S. aureus*, AMC: amoxicillin-clavulanate, TZP: piperacillin-tazobactam, SXT: trimethoprim-sulfamethoxazole.

Table 2. Top 20 bacterial pathogens isolated from Canadian ICUs.

RANK	ORGANISM	N	% TOTAL
1	<i>Staphylococcus aureus</i>	1466	21
2	<i>Pseudomonas aeruginosa</i>	724	10.4
3	<i>Escherichia coli</i>	718	10.3
4	<i>Streptococcus pneumoniae</i>	474	6.8
5	<i>Klebsiella pneumoniae</i>	439	6.3
6	<i>Haemophilus influenzae</i>	351	5
7	<i>Enterobacter cloacae</i>	317	4.5
8	<i>Staphylococcus epidermidis</i>	226	3.2
9	<i>Serratia marcescens</i>	192	2.8
10	<i>Stenotrophomonas maltophilia</i>	192	2.8
11	<i>Enterococcus faecalis</i>	179	2.6
12	<i>Klebsiella oxytoca</i>	151	2.2
13	<i>Enterococcus faecium</i>	110	1.6
14	<i>Moraxella catarrhalis</i>	105	1.5
15	<i>Enterobacter aerogenes</i>	93	1.3
16	<i>Acinetobacter baumannii</i>	61	0.9
17	<i>Proteus mirabilis</i>	60	0.9
18	<i>Morganella morganii</i>	26	0.4
19	<i>Citrobacter freundii</i>	25	0.4
20	Other	1068	15.3

Figure 1. Patient demographics.

